Regenxbio Inc (RGNX)
8.77
-0.02
(-0.23%)
USD |
NASDAQ |
Nov 04, 16:00
8.765
0.00 (0.00%)
After-Hours: 20:00
Regenxbio Revenue (Quarterly): 22.30M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 22.30M |
| March 31, 2024 | 15.62M |
| December 31, 2023 | 22.21M |
| September 30, 2023 | 28.91M |
| June 30, 2023 | 19.98M |
| March 31, 2023 | 19.14M |
| December 31, 2022 | 31.34M |
| September 30, 2022 | 26.51M |
| June 30, 2022 | 32.65M |
| March 31, 2022 | 22.22M |
| December 31, 2021 | 398.66M |
| September 30, 2021 | 30.77M |
| June 30, 2021 | 22.04M |
| March 31, 2021 | 18.88M |
| December 31, 2020 | 21.44M |
| September 30, 2020 | 98.91M |
| June 30, 2020 | 16.57M |
| March 31, 2020 | 17.64M |
| December 31, 2019 | 11.77M |
| September 30, 2019 | 14.70M |
| Date | Value |
|---|---|
| June 30, 2019 | 7.881M |
| March 31, 2019 | 0.884M |
| December 31, 2018 | 40.78M |
| September 30, 2018 | 5.306M |
| June 30, 2018 | 40.03M |
| March 31, 2018 | 132.39M |
| December 31, 2017 | 2.04M |
| September 30, 2017 | 1.336M |
| June 30, 2017 | 6.562M |
| March 31, 2017 | 0.455M |
| December 31, 2016 | 1.696M |
| September 30, 2016 | 0.125M |
| June 30, 2016 | 2.375M |
| March 31, 2016 | 0.393M |
| December 31, 2015 | 4.448M |
| September 30, 2015 | 1.14M |
| June 30, 2015 | 1.363M |
| March 31, 2015 | 0.644M |
| December 31, 2014 | 1.148M |
| September 30, 2014 | 0.483M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
11.77M
Minimum
Dec 2019
398.66M
Maximum
Dec 2021
46.19M
Average
22.21M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 362.93M |
| Catalyst Pharmaceuticals Inc | 122.71M |
| Vertex Pharmaceuticals Inc | 2.646B |
| Edgewise Therapeutics Inc | -- |
| Entrada Therapeutics Inc | 94.69M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -52.99M |
| Total Expenses (Quarterly) | 78.33M |
| EPS Diluted (Quarterly) | -1.05 |
| Enterprise Value | 144.07M |
| Gross Profit Margin (Quarterly) | 52.55% |
| Profit Margin (Quarterly) | -237.7% |
| Earnings Yield | -59.98% |
| Normalized Earnings Yield | -62.67 |